title: Complete pathological response after sequential therapy with sunitinib and radiotherapy for metastatic clear cell renal carcinoma.
abstract: Despite great improvements in the management of metastatic clear cell renal carcinoma, complete responses with antiangiogenic therapies are infrequent and complete pathological responses remain anecdotal. We report the complete pathological response of a solitary bone metastasis from a clear cell renal carcinoma after sequential treatment with sunitinib and radiotherapy. In February 2009, a female patient was diagnosed with clear cell renal carcinoma of the left kidney, bearing only one metastatic site localized in the proximal extremity of the left tibia. Radical nephrectomy was performed at first. Thereafter, sunitinib was administered at standard dose level for four weeks followed by two weeks free at each cycle. The patient underwent palliative radiotherapy between the fifth and the sixth cycle. Due to stable status, a radical surgery of the left knee was then performed and pathological analysis concluded a complete response. This case highlights potential synergy between sunitinib and radiation therapy in clear cell renal carcinoma.
authors.affiliation: Medical Oncology Unit, La Timone Hospital, 264 Rue Saint Pierre, 13385 Marseilles cedex 5, France.
authors.forename: Geoffroy
authors.initials: G
authors.lastname: Venton
authors.forename: Aurelie
authors.initials: A
authors.lastname: Ducournau
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Gross
authors.forename: Eric
authors.initials: E
authors.lastname: Lechevallier
authors.forename: Alexandre
authors.initials: A
authors.lastname: Rochwerger
authors.forename: Georges
authors.initials: G
authors.lastname: Curvale
authors.forename: Jean-Vincent
authors.initials: JV
authors.lastname: Zink
authors.forename: Sebastien
authors.initials: S
authors.lastname: Salas
authors.forename: Jean-Laurent
authors.initials: JL
authors.lastname: Deville
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary* / Q000628:therapy*; D002292:Carcinoma, Renal Cell / Q000473:pathology / Q000532:radiotherapy / Q000556:secondary* / Q000628:therapy*; D059248:Chemoradiotherapy; D005260:Female; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D008875:Middle Aged; D010166:Palliative Care / Q000379:methods; D011758:Pyrroles / Q000627:therapeutic use*; D000077210:Sunitinib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib